Macomics
  • About us
    • About us
    • Team
    • Board
    • Scientific Advisors
    • Investors
  • Science
    • Science
    • Publications
  • Pipeline
  • Partnering
  • News & Events
    • News
    • Events
  • Working Here
  • Contact us

Author: edgover

Macomics secures £3.2 million seed funding

Posted on 14 July 20209 May 2025 by edgover

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.

Posted in Uncategorized

Posts navigation

Newer posts

Recent Posts

  • Macomics Team Scores Gold and Raises Over £600 in its Hyper-Triathlon Challenge in aid of Founder Prof. Jeffrey Pollard’s Memorial Fund
  • Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
  • Macomics Announces Appointment of Simon Dew as New Chief Business Officer
  • Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
  • Macomics Unveils its Lead First-in-Class Anti-Pan-LILR Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024

Recent Comments

No comments to show.

Archives

  • August 2024
  • June 2024
  • May 2024
  • April 2024
  • October 2023
  • September 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • May 2022
  • January 2022
  • November 2021
  • October 2021
  • July 2021
  • May 2021
  • March 2021
  • July 2020

Categories

  • Uncategorized
TERMS OF USE
PRIVACY POLICY & COOKIES
© COPYRIGHT 2025 MACOMICS
 Follow us on LinkedIn